Kerry Group

KRYAY | OTC

Price Alert Chart Builder DCF Calculator

$109.16

$0.00 (0.00%)

Nov 2, 2026, 9:51 AM ET · Market open

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+0.00%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

42.9

-3.0 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #157/297 (Top 53%)

Full Analysis

Key Statistics

Market Data

Market Cap $17.35B

1D Range

108.90 109.87

52W Range

74.85 112.39

Valuation (TTM)

PE 23.87

PB 2.50

EV/EBITDA 14.47

Valuation (NTM)

Forward PE 17.38

Forward PEG 3.80

Price Target $0.00

Cash Flow

FCF Yield 2.9%

SBC Adj. FCF Yield 2.9%

SBC Impact N/A

Margins

Gross Margin 40.0%

Operating Margin 16.6%

FCF Margin 6.9%

Growth (CAGR)

Revenue 3Y | 5Y -2.2% | 1.6%

Dil EPS 3Y | 5Y 8.8% | 6.3%

FCF 3Y | 5Y 3.9% | -6.2%

Returns

ROA 7.1%

ROE 13.1%

ROIC 10.1%

Financial Health

Net Debt

€2.23B ($2.55B)

Current Ratio 1.77

Interest Coverage 14.74

Dividends

Div Yield 1.54%

Payout Ratio 42.8%

FCF Payout Ratio 49.4%

All Key Statistics

Loading financial charts...

Profile

Kerry Group plc, together with its various subsidiaries, is dedicated to conceiving, formulating, and furnishing cutting-edge taste and nutritional offerings. These solutions are provided to the food,...

Sector Consumer Defensive

Industry Packaged Foods

Employees 19,420

IPO Date Jan 30, 2008

Website www.kerry.com

Fiscal Year n/a

Full Company Profile

Latest News

21 days ago · seekingalpha.com

Kerry Group plc (KRYAY) Analyst/Investor Day Transcript

24 days ago · marketbeat.com

Kerry Group Targets 20%-21% Margins as Biotech Fuels Taste and Nutrition Growth

Kerry Group LON: KYGA said it is positioning its technology portfolio, biotechnology capabilities and customer-focused application expertise to capture growing food and beverage innovation and renovation opportunities, particularly as consumers demand healthier, more affordable and differentiated products.

1 month ago · newsfilecorp.com

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic™(OST-HER2; daznelimgene lisbac) Grasonville, Maryland--(Newsfile Corp. - October 1, 2026) - OS Therapies, Inc . (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced the appointment of Kerry Clem as Chief Commercial Officer (CCO) and Frank Knuettel II as Chief Financial Officer (CFO).

2 months ago · zacks.com

All You Need to Know About Kerry Group (KRYAY) Rating Upgrade to Buy

Kerry Group (KRYAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago · seekingalpha.com

Kerry Group plc (KRYAY) Q2 2026 Earnings Call Prepared Remarks Transcript

3 months ago · seekingalpha.com

Kerry Group plc (KRYAY) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Kerry Group plc (KRYAY) Discusses Half Year Results, Margin Expansion and 2030 Financial Targets Prepared Remarks Transcript

4 months ago · zacks.com

HFFG vs. KRYAY: Which Stock Is the Better Value Option?

Investors interested in stocks from the Food - Miscellaneous sector have probably already heard of HF FOODS GROUP INC. (HFFG) and Kerry Group PLC (KRYAY).